ArticleFrontiers in physiology2021

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload.

Sophia L Young et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.